LOLLI, CRISTIAN
LOLLI, CRISTIAN
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer
2025 Conteduca, V.; Scarpi, E.; Rossi, A.; Ferroni, F.; Gurioli, G.; Bleve, S.; Gianni, C.; Schepisi, G.; Brighi, N.; Lolli, C.; Cursano, M. C.; Virga, A.; Casadei, C.; Altavilla, A.; Farolfi, A.; Ulivi, P.; Barone, D.; Matteucci, F.; De Giorgi, U.
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience
2025 Bruno, Giuseppina; Natalicchio, Maria Iole; Garofoli, Marianna; Lolli, Cristian; Rosano, Aldo; Tullio, Piergiorgio Di; Giordano, Guido; Mancino, Alice; Masucci, Mariachiara; Chiuri, Vincenzo Emanuele; Fratino, Lucia; Zanardi, Elisa; Schepisi, Giuseppe; Galli, Luca; Massari, Francesco; Santoni, Matteo; Brighi, Nicole; Cornacchia, Elisabetta; Rescigno, Pasquale; Fornarini, Giuseppe; Sanguedolce, Francesca; Santini, Daniele; Procopio, Giuseppe; Caffo, Orazio; Giorgi, Ugo De; Landriscina, Matteo; Conteduca, Vincenza
Correlation of [68Ga]Ga-PSMA PET/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective study
2024 Francesco Giunta, Emilio; Caroli, Paola; Scarpi, Emanuela; Altavilla, Amelia; Marini, Irene; Celli, Monica; Casadei, Chiara; Lolli, Cristian; Schepisi, Giuseppe; Bleve, Sara; Brighi, Nicole; Concetta Cursano, Maria; Martinelli, Giovanni; Matteucci, Federica; De Giorgi, Ugo Federico Francesco
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients
2024 Giunta, E. F.; Caroli, P.; Scarpi, E.; Altavilla, A.; Rossetti, V.; Marini, I.; Celli, M.; Casadei, C.; Lolli, C.; Schepisi, G.; Bleve, S.; Brighi, N.; Cursano, M. C.; Paganelli, G.; Matteucci, F.; De Giorgi, U.
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study
2024 Casadei C.; Scarpi E.; Conteduca V.; Gurioli G.; Cursano M.C.; Brighi N.; Lolli C.; Schepisi G.; Basso U.; Fornarini G.; Bleve S.; Farolfi A.; Altavilla A.; Burgio S.L.; Giunta E.F.; Gianni C.; Filograna A.; Ulivi P.; Olmos D.; Castro E.; De Giorgi U.
Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors
2023 Schepisi, G.; Gianni, C.; Cursano, M. C.; Galla, V.; Menna, C.; Casadei, C.; Bleve, S.; Lolli, C.; Martinelli, G.; Rosti, G.; De Giorgi, U.
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
2023 Farolfi A.; Petracci E.; Gurioli G.; Tedaldi G.; Casanova C.; Arcangeli V.; Amadori A.; Rosati M.; Stefanetti M.; Burgio S.L.; Cursano M.C.; Lolli C.; Zampiga V.; Cangini I.; Schepisi G.; De Giorgi U,
Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial
2023 Brighi, N.; Conteduca, V.; Gurioli, G.; Scarpi, E.; Cursano, M. C.; Bleve, S.; Lolli, C.; Schepisi, G.; Casadei, C.; Gianni, C.; Ulivi, P.; De Giorgi, U.
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer
2022 Cursano, M. C.; Conteduca, V.; Scarpi, E.; Gurioli, G.; Casadei, C.; Gargiulo, S.; Altavilla, A.; Lolli, C.; Vincenzi, B.; Tonini, G.; Santini, D.; De Giorgi, U.
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA
2021 Conteduca V.; Brighi N.; Conteduca D.; Bleve S.; Gianni C.; Schepisi G.; Iaia M.L.; Gurioli G.; Lolli C.; De Giorgi U.
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome
2021 Conteduca V.; Scarpi E.; Caroli P.; Lolli C.; Gurioli G.; Brighi N.; Poti G.; Farolfi A.; Altavilla A.; Schepisi G.; Matteucci F.; Paganelli G.; De Giorgi U.
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging
2021 Conteduca V.; Poti G.; Caroli P.; Russi S.; Brighi N.; Lolli C.; Schepisi G.; Romeo A.; Matteucci F.; Paganelli G.; Marchetti P.; De Giorgi U.
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy
2021 Schepisi G.; Casadei C.; Toma I.; Poti G.; Iaia M.L.; Farolfi A.; Conteduca V.; Lolli C.; Ravaglia G.; Brighi N.; Altavilla A.; Martinelli G.; De Giorgi U.
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study
2021 Conteduca V.; Wetterskog D.; Castro E.; Scarpi E.; Romero-Laorden N.; Gurioli G.; Jayaram A.; Lolli C.; Schepisi G.; Wingate A.; Casadei C.; Lozano R.; Brighi N.; Aragon I.M.; Marin-Aguilera M.; Gonzalez-Billalabeitia E.; Mellado B.; Olmos D.; Attard G.; De Giorgi U.
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients
2021 Conteduca V.; Scarpi E.; Wetterskog D.; Brighi N.; Ferroni F.; Rossi A.; Romanel A.; Gurioli G.; Bleve S.; Gianni C.; Schepisi G.; Lolli C.; Cortesi P.; Matteucci F.; Barone D.; Paganelli G.; Demichelis F.; Beltran H.; Attard G.; De Giorgi U.
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives
2021 Brighi N.; Conteduca V.; Lolli C.; Gurioli G.; Schepisi G.; Palleschi M.; Mariotti M.; Casadei C.; De Giorgi U.
Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review
2021 Schepisi, G.; Gianni, C.; Bleve, S.; De Padova, S.; Menna, C.; Lolli, C.; Filograna, A.; Conteduca, V.; Urbini, M.; Galla, V.; Casadei, C.; Rosti, G.; De Giorgi, U.
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma
2020 Lolli C.; Altavilla A.; Conteduca V.; Farolfi A.; Casadei C.; Schepisi G.; Banna G.L.; De Giorgi U.
Immune modulation in prostate cancer patients treated with androgen receptor (Ar)-targeted therapy
2020 Conteduca V.; Caffo O.; Scarpi E.; Sepe P.; Galli L.; Fratino L.; Maines F.; Chiuri V.E.; Santoni M.; Zanardi E.; Massari F.; Toma I.; Lolli C.; Schepisi G.; Sbrana A.; Kinspergher S.; Cursano M.C.; Casadei C.; Modonesi C.; Santini D.; Procopio G.; De Giorgi U.
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
2020 Gurioli G.; Conteduca V.; Lolli C.; Schepisi G.; Gargiulo S.; Altavilla A.; Casadei C.; Scarpi E.; De Giorgi U.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer | Conteduca, V.; Scarpi, E.; Rossi, A.; Ferroni, F.; Gurioli, G.; Bleve, S.; Gianni, C.; Schepisi, ...G.; Brighi, N.; Lolli, C.; Cursano, M. C.; Virga, A.; Casadei, C.; Altavilla, A.; Farolfi, A.; Ulivi, P.; Barone, D.; Matteucci, F.; De Giorgi, U. | 2025-01-01 | THE ONCOLOGIST | - | 1.01 Articolo in rivista | oyaf107_suppl_supplementary_tables_1-7_figures_1.docx; oyaf107.pdf |
| Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience | Bruno, Giuseppina; Natalicchio, Maria Iole; Garofoli, Marianna; Lolli, Cristian; Rosano, Aldo; Tu...llio, Piergiorgio Di; Giordano, Guido; Mancino, Alice; Masucci, Mariachiara; Chiuri, Vincenzo Emanuele; Fratino, Lucia; Zanardi, Elisa; Schepisi, Giuseppe; Galli, Luca; Massari, Francesco; Santoni, Matteo; Brighi, Nicole; Cornacchia, Elisabetta; Rescigno, Pasquale; Fornarini, Giuseppe; Sanguedolce, Francesca; Santini, Daniele; Procopio, Giuseppe; Caffo, Orazio; Giorgi, Ugo De; Landriscina, Matteo; Conteduca, Vincenza | 2025-01-01 | EUROPEAN UROLOGY ONCOLOGY | - | 1.01 Articolo in rivista | EUO 2025 [Mol Prof Lung mets mCRPC].pdf; ScienceDirect_files_04Jun2025_12-04-05.239.zip |
| Correlation of [68Ga]Ga-PSMA PET/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective study | Francesco Giunta, Emilio; Caroli, Paola; Scarpi, Emanuela; Altavilla, Amelia; Marini, Irene; Cell...i, Monica; Casadei, Chiara; Lolli, Cristian; Schepisi, Giuseppe; Bleve, Sara; Brighi, Nicole; Concetta Cursano, Maria; Martinelli, Giovanni; Matteucci, Federica; De Giorgi, Ugo Federico Francesco | 2024-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients | Giunta, E. F.; Caroli, P.; Scarpi, E.; Altavilla, A.; Rossetti, V.; Marini, I.; Celli, M.; Casade...i, C.; Lolli, C.; Schepisi, G.; Bleve, S.; Brighi, N.; Cursano, M. C.; Paganelli, G.; Matteucci, F.; De Giorgi, U. | 2024-01-01 | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | - | 1.01 Articolo in rivista | 259_2024_Article_6887.pdf; 259_2024_6887_MOESM2_ESM.docx; 259_2024_6887_MOESM1_ESM.docx |
| Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study | Casadei C.; Scarpi E.; Conteduca V.; Gurioli G.; Cursano M.C.; Brighi N.; Lolli C.; Schepisi G.; ...Basso U.; Fornarini G.; Bleve S.; Farolfi A.; Altavilla A.; Burgio S.L.; Giunta E.F.; Gianni C.; Filograna A.; Ulivi P.; Olmos D.; Castro E.; De Giorgi U. | 2024-01-01 | EUROPEAN UROLOGY OPEN SCIENCE | - | 1.01 Articolo in rivista | Inherited Mutations in DNA Damage Repair Genes from Meet-URO 10 Study.pdf |
| Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors | Schepisi, G.; Gianni, C.; Cursano, M. C.; Galla, V.; Menna, C.; Casadei, C.; Bleve, S.; Lolli, C....; Martinelli, G.; Rosti, G.; De Giorgi, U. | 2023-01-01 | FRONTIERS IN IMMUNOLOGY | - | 1.01 Articolo in rivista | fimmu-14-1118610.pdf |
| Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients | Farolfi A.; Petracci E.; Gurioli G.; Tedaldi G.; Casanova C.; Arcangeli V.; Amadori A.; Rosati M....; Stefanetti M.; Burgio S.L.; Cursano M.C.; Lolli C.; Zampiga V.; Cangini I.; Schepisi G.; De Giorgi U, | 2023-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | fonc-13-1221096.pdf; Table_1 .docx |
| Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial | Brighi, N.; Conteduca, V.; Gurioli, G.; Scarpi, E.; Cursano, M. C.; Bleve, S.; Lolli, C.; Schepis...i, G.; Casadei, C.; Gianni, C.; Ulivi, P.; De Giorgi, U. | 2023-01-01 | ESMO OPEN | - | 1.01 Articolo in rivista | main (1).pdf; 1-s2.0-S2059702923012772-mmc1.docx |
| Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer | Cursano, M. C.; Conteduca, V.; Scarpi, E.; Gurioli, G.; Casadei, C.; Gargiulo, S.; Altavilla, A.;... Lolli, C.; Vincenzi, B.; Tonini, G.; Santini, D.; De Giorgi, U. | 2022-01-01 | SCIENTIFIC REPORTS | - | 1.01 Articolo in rivista | Grade group system.pdf |
| An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA | Conteduca V.; Brighi N.; Conteduca D.; Bleve S.; Gianni C.; Schepisi G.; Iaia M.L.; Gurioli G.; L...olli C.; De Giorgi U. | 2021-01-01 | EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | - | 1.01 Articolo in rivista | - |
| Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome | Conteduca V.; Scarpi E.; Caroli P.; Lolli C.; Gurioli G.; Brighi N.; Poti G.; Farolfi A.; Altavil...la A.; Schepisi G.; Matteucci F.; Paganelli G.; De Giorgi U. | 2021-01-01 | MOLECULAR ONCOLOGY | - | 1.01 Articolo in rivista | Molecular Oncology - 2021 - Conteduca - Combining liquid biopsy and functional imaging analysis in metastatic.pdf; Supplementary materials.zip |
| Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging | Conteduca V.; Poti G.; Caroli P.; Russi S.; Brighi N.; Lolli C.; Schepisi G.; Romeo A.; Matteucci... F.; Paganelli G.; Marchetti P.; De Giorgi U. | 2021-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | 1758835920987654.pdf |
| Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy | Schepisi G.; Casadei C.; Toma I.; Poti G.; Iaia M.L.; Farolfi A.; Conteduca V.; Lolli C.; Ravagli...a G.; Brighi N.; Altavilla A.; Martinelli G.; De Giorgi U. | 2021-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-13-00840-v2.pdf |
| Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study | Conteduca V.; Wetterskog D.; Castro E.; Scarpi E.; Romero-Laorden N.; Gurioli G.; Jayaram A.; Lol...li C.; Schepisi G.; Wingate A.; Casadei C.; Lozano R.; Brighi N.; Aragon I.M.; Marin-Aguilera M.; Gonzalez-Billalabeitia E.; Mellado B.; Olmos D.; Attard G.; De Giorgi U. | 2021-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients | Conteduca V.; Scarpi E.; Wetterskog D.; Brighi N.; Ferroni F.; Rossi A.; Romanel A.; Gurioli G.; ...Bleve S.; Gianni C.; Schepisi G.; Lolli C.; Cortesi P.; Matteucci F.; Barone D.; Paganelli G.; Demichelis F.; Beltran H.; Attard G.; De Giorgi U. | 2021-01-01 | INTERNATIONAL JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives | Brighi N.; Conteduca V.; Lolli C.; Gurioli G.; Schepisi G.; Palleschi M.; Mariotti M.; Casadei C....; De Giorgi U. | 2021-01-01 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review | Schepisi, G.; Gianni, C.; Bleve, S.; De Padova, S.; Menna, C.; Lolli, C.; Filograna, A.; Conteduc...a, V.; Urbini, M.; Galla, V.; Casadei, C.; Rosti, G.; De Giorgi, U. | 2021-01-01 | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - | 1.01 Articolo in rivista | - |
| A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma | Lolli C.; Altavilla A.; Conteduca V.; Farolfi A.; Casadei C.; Schepisi G.; Banna G.L.; De Giorgi U. | 2020-01-01 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Immune modulation in prostate cancer patients treated with androgen receptor (Ar)-targeted therapy | Conteduca V.; Caffo O.; Scarpi E.; Sepe P.; Galli L.; Fratino L.; Maines F.; Chiuri V.E.; Santoni... M.; Zanardi E.; Massari F.; Toma I.; Lolli C.; Schepisi G.; Sbrana A.; Kinspergher S.; Cursano M.C.; Casadei C.; Modonesi C.; Santini D.; Procopio G.; De Giorgi U. | 2020-01-01 | JOURNAL OF CLINICAL MEDICINE | - | 1.01 Articolo in rivista | Journal Clinical Medicine [Conteduca].pdf |
| Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide | Gurioli G.; Conteduca V.; Lolli C.; Schepisi G.; Gargiulo S.; Altavilla A.; Casadei C.; Scarpi E....; De Giorgi U. | 2020-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | - |